Association between interferon use and reduced metabolic and vascular complications among patients with hepatitis C.We examined whether interferon treatment is associated with reduced metabolic/vascular complications in hepatitis C virus patients.  Interferon-treated and -untreated hepatitis C virus patients were matched on baseline covariates.  Using multivariate counting process Cox regressions, we modeled the association between interferon receipt of at least 24 weeks and DCSI events incidence rate. 
interferon
Association between interferon use and reduced metabolic and vascular complications among patients with hepatitis C.We examined whether interferon treatment is associated with reduced metabolic/vascular complications in hepatitis C virus patients.  Interferon-treated and -untreated hepatitis C virus patients were matched on baseline covariates.  Using multivariate counting process Cox regressions, we modeled the association between interferon receipt of at least 24 weeks and DCSI events incidence rate. 
interferon
The study had historical prospective cohort design using Maryland Medicaid administrative data (2006-2009). 
Medicaid administrative data
Using multivariate counting process Cox regressions, we modeled the association between interferon receipt of at least 24 weeks and DCSI events incidence rate. 
Cox regressions
Association between interferon use and reduced metabolic and vascular complications among patients with hepatitis C.We examined whether interferon treatment is associated with reduced metabolic/vascular complications in hepatitis C virus patients.  Interferon-treated and -untreated hepatitis C virus patients were matched on baseline covariates.  Using multivariate counting process Cox regressions, we modeled the association between interferon receipt of at least 24 weeks and DCSI events incidence rate. 
interferon